Source:http://linkedlifedata.com/resource/pubmed/id/20971083
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2011-1-3
|
| pubmed:abstractText |
Blood-brain-barrier (BBB) breakdown due to matrix metalloproteinase (MMP) activity following stroke is often associated with cerebral edema, larger infarct volumes and bad outcome. In the present study we examined a novel MMP-inhibitor (Ro 28-2653) with high selectivity for MMP2, MMP9 and membrane type 1-MMP in an acute stroke model comparing two different treatment regimens. We subjected rats to 90 min of focal cerebral ischemia followed by 3 days or 7 days of reperfusion, respectively, using the middle cerebral artery (MCA) filament occlusion technique. Ro 28-2653 was administered daily in a vehicle solution for 2 days or 6 days after ischemia, respectively. We assessed the behavior with a functional neuroscore and infarct volumes as well as blood-brain-barrier (BBB) breakdown with magnetic resonance imaging (MRI) after 3 and 7 days. Infarct edema volumes, BBB breakdown and behavior at 3 days were significantly attenuated in rats treated for 2 days with Ro 28-2653 as compared to vehicle and untreated controls. After 6 days of treatment however, infarct and BBB breakdown volumes as well as behavior did not differ significantly between the groups at 7 days. The new high selective MMP-inhibitor Ro 28-2653 significantly reduced brain injury only when administered in the first 2 days after focal cerebral ischemia. Prolonged treatment for 6 days did not show any beneficial effects possibly due to interference with protective restorative processes.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 9,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/Ro 28-2653
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1872-6240
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright © 2010 Elsevier B.V. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
12
|
| pubmed:volume |
1368
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
264-70
|
| pubmed:meshHeading |
pubmed-meshheading:20971083-Animals,
pubmed-meshheading:20971083-Behavior, Animal,
pubmed-meshheading:20971083-Blood-Brain Barrier,
pubmed-meshheading:20971083-Disease Models, Animal,
pubmed-meshheading:20971083-Edema,
pubmed-meshheading:20971083-Infarction, Middle Cerebral Artery,
pubmed-meshheading:20971083-Magnetic Resonance Imaging,
pubmed-meshheading:20971083-Male,
pubmed-meshheading:20971083-Matrix Metalloproteinase 1,
pubmed-meshheading:20971083-Matrix Metalloproteinase 2,
pubmed-meshheading:20971083-Matrix Metalloproteinase 9,
pubmed-meshheading:20971083-Piperazines,
pubmed-meshheading:20971083-Pyrimidines,
pubmed-meshheading:20971083-Rats,
pubmed-meshheading:20971083-Rats, Wistar,
pubmed-meshheading:20971083-Reperfusion,
pubmed-meshheading:20971083-Stroke,
pubmed-meshheading:20971083-Time Factors,
pubmed-meshheading:20971083-Treatment Outcome
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Selective MMP-inhibition with Ro 28-2653 in acute experimental stroke--a magnetic resonance imaging efficacy study.
|
| pubmed:affiliation |
Department of Neurology, University of Heidelberg, Heidelberg, Germany.
|
| pubmed:publicationType |
Journal Article
|